Regeneron Pharmaceuticals, Inc. $REGN Stock Acquired by First Trust Advisors LP

First Trust Advisors LP raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 51.1% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 826,770 shares of the biopharmaceutical company’s stock after acquiring an additional 279,638 shares during the quarter. First Trust Advisors LP’s holdings in Regeneron Pharmaceuticals were worth $626,915,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $5,682,636,000. Legal & General Group Plc bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at $473,872,000. Bank of New York Mellon Corp bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at $472,950,000. Aberdeen Group plc lifted its holdings in shares of Regeneron Pharmaceuticals by 560.7% during the third quarter. Aberdeen Group plc now owns 671,042 shares of the biopharmaceutical company’s stock valued at $508,831,000 after purchasing an additional 569,476 shares in the last quarter. Finally, Deutsche Bank AG bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at $323,249,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $920.69 on Friday. The firm has a market cap of $95.25 billion, a PE ratio of 20.33, a P/E/G ratio of 1.22 and a beta of 0.10. The company has a current ratio of 3.35, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a fifty day simple moving average of $829.76 and a two-hundred day simple moving average of $752.07. Regeneron Pharmaceuticals, Inc. has a 1-year low of $591.52 and a 1-year high of $991.73.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating the consensus estimate of $16.51 by $3.56. The firm had revenue of $5.12 billion for the quarter, compared to analysts’ expectations of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The company’s revenue was up 36.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $11.83 EPS. On average, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 58.26 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 8.30%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Barclays increased their price objective on Regeneron Pharmaceuticals from $917.00 to $1,075.00 and gave the company an “overweight” rating in a research report on Tuesday, November 17th. Bank of America boosted their target price on Regeneron Pharmaceuticals from $908.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Monday, November 2nd. Cantor Fitzgerald upped their target price on shares of Regeneron Pharmaceuticals from $795.00 to $980.00 and gave the company an “overweight” rating in a research note on Monday, November 2nd. BMO Capital Markets upped their target price on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company an “outperform” rating in a research note on Wednesday, September 9th. Finally, Morgan Stanley raised their price target on shares of Regeneron Pharmaceuticals from $779.00 to $855.00 and gave the company an “equal weight” rating in a report on Monday, November 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $904.41.

View Our Latest Stock Analysis on Regeneron Pharmaceuticals

Key Headlines Impacting Regeneron Pharmaceuticals

Here are a few of the latest headlines about REGN:

  • Positive Sentiment: The European Commission approved more flexible Libtayo dosing across six cancer indications. The change could improve convenience for patients and support Regeneron’s oncology business. Libtayo dosing flexibility approval
  • Positive Sentiment: Regeneron plans to present new hematology data at the December ASH meeting, including potentially pivotal Ordspono results in marginal zone lymphoma. The data could provide further evidence of the company’s pipeline opportunity, though it is not yet a clinical or regulatory outcome. Regeneron ASH data announcement
  • Neutral Sentiment: Director Andrew Murphy sold 5,011 shares under a pre-arranged Rule 10b5-1 plan. He retained 46,779 shares afterward, making the transaction a limited signal about his view of the company. Insider transaction report

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Kathryn Guarini sold 400 shares of the stock in a transaction dated Friday, October 30th. The stock was sold at an average price of $900.00, for a total value of $360,000.00. Following the transaction, the director owned 603 shares of the company’s stock, valued at approximately $542,700. This represents a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christine Poon sold 7,830 shares of the firm’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $969.09, for a total value of $7,587,974.70. Following the completion of the transaction, the director directly owned 5,219 shares in the company, valued at $5,057,680.71. The trade was a 60.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 32,039 shares of company stock valued at $29,825,285 in the last 90 days. 6.97% of the stock is owned by company insiders.

About Regeneron Pharmaceuticals

(Free Report)

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Read More

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.